{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:17Z","timestamp":1791328877854,"version":"4.3.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>BAY 94-8862 is a novel, non-steroidal, mineralocorticoid receptor antagonist with greater selectivity than spironolactone and stronger mineralocorticoid receptor binding affinity than eplerenone. The aims of the MinerAlocorticoid Receptor Antagonist Tolerability Study (ARTS; NCT01345656) are to evaluate the safety and tolerability of BAY 94-8862 in patients with heart failure associated with a reduced left ventricular ejection fraction (HFREF) and chronic kidney disease (CKD), and to examine the effects on biomarkers of cardiac and renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ARTS is a multicentre, randomized, double-blind, placebo-controlled, parallel-group study divided into two parts. In part A, oral BAY 94-8862 [2.5, 5, or 10 mg once daily (o.d.)] is compared with placebo in ~60 patients with HFREF and mild CKD. Outcome measures include serum potassium concentration, biomarkers of renal injury, estimated glomerular filtration rate (eGFR), and albuminuria. Part B compares BAY 94-8862 (2.5, 5, or 10 mg o.d., or 5 mg twice daily), placebo, and open-label spironolactone (25\u201350 mg o.d.) in ~360 patients with HFREF and moderate CKD. Outcome measures include the change in serum potassium concentration with BAY 94-8862 vs. placebo (primary endpoint) and vs. spironolactone, safety and tolerability, biomarkers of cardiac and renal function or injury, eGFR, and albuminuria. BAY 94-8862 pharmacokinetics are also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Perspectives<\/jats:title>\n                    <jats:p>ARTS is the first phase II clinical trial of BAY 94-8862 and is expected to provide a wealth of information on BAY 94-8862 in patients with HFREF and CKD, including the optimal dose range for further studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfs061","type":"journal-article","created":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T20:55:48Z","timestamp":1336251348000},"page":"668-675","source":"Crossref","is-referenced-by-count":85,"title":["Rationale and Design of ARTS: A Randomized, Double-Blind Study of BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease"],"prefix":"10.1093","volume":"14","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[{"name":"University of Michigan School of Medicine , Ann Arbor, MI, 48109-0366 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Department of Cardiology, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kober","sequence":"additional","affiliation":[{"name":"Heart Centre, Rigshospitalet, University of Copenhagen \u00a0","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Medical University, Clinical Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Nowack","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Bayer Pharma AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[{"name":"Cardiology Research, Department of Heart Diseases, Global Drug Discovery, Bayer HealthCare Pharmaceuticals , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Bayer Vital GmbH, Bayer HealthCare , Leverkusen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"INSERM, Centre for Clinical Investigation 9501 and Unit 961, Central University Hospital and the Department of Cardiology, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"2026011921180938900_ejhfhfs061-bib-0001","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10741-011-9280-0","article-title":"A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial","volume":"17","author":"Gheorghiade","year":"2012","journal-title":"Heart Fail Rev"},{"key":"2026011921180938900_ejhfhfs061-bib-0002","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","article-title":"CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin\u2013angiotensin\u2013aldosterone system the cornerstone of therapy for systolic heart failure","volume":"13","author":"McMurray","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011921180938900_ejhfhfs061-bib-0003","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921180938900_ejhfhfs061-bib-0004","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011921180938900_ejhfhfs061-bib-0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921180938900_ejhfhfs061-bib-0006","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011921180938900_ejhfhfs061-bib-0007","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics","volume":"13","author":"Epstein","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026011921180938900_ejhfhfs061-bib-0008","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"2026011921180938900_ejhfhfs061-bib-0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026011921180938900_ejhfhfs061-bib-0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2215\/CJN.01340209","article-title":"Mineralocorticoid receptor blockers and chronic kidney disease","volume":"4","author":"Jain","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026011921180938900_ejhfhfs061-bib-0011","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"3","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011921180938900_ejhfhfs061-bib-0012","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026011921180938900_ejhfhfs061-bib-0013","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"2026011921180938900_ejhfhfs061-bib-0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.108.772228","article-title":"Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF","volume":"1","author":"Fonarow","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2026011921180938900_ejhfhfs061-bib-0015","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/eurjhf\/hfq154","article-title":"EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"12","author":"Maggioni","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921180938900_ejhfhfs061-bib-0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"2026011921180938900_ejhfhfs061-bib-0017","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"2026011921180938900_ejhfhfs061-bib-0018","first-page":"780","volume-title":"Goodman & Gilman's: The Pharmacological Basis of Therapeutics","author":"Jackson","year":"2001","edition":"10th ed"},{"key":"2026011921180938900_ejhfhfs061-bib-0019","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"2026011921180938900_ejhfhfs061-bib-0020","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"2026011921180938900_ejhfhfs061-bib-0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ncpendmet0016","article-title":"Mineralocorticoid-receptor blockade, hypertension and heart failure","volume":"1","author":"Funder","year":"2005","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2026011921180938900_ejhfhfs061-bib-0022","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026011921180938900_ejhfhfs061-bib-0023","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/eurheartj\/ehr170","article-title":"Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes","volume":"32","author":"Albaghdadi","year":"2011","journal-title":"Eur Heart J"},{"key":"2026011921180938900_ejhfhfs061-bib-0024","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026011921180938900_ejhfhfs061-bib-0025","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"2026011921180938900_ejhfhfs061-bib-0026","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a non-steroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"2026011921180938900_ejhfhfs061-bib-0027","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm1002827","article-title":"Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"2026011921180938900_ejhfhfs061-bib-0028","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"2026011921180938900_ejhfhfs061-bib-0029","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs061","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfs061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfs061","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/14\/6\/668\/66442794\/eurjhf_14_6_668.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/14\/6\/668\/66442794\/eurjhf_14_6_668.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:24:08Z","timestamp":1768875848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/14\/6\/668\/8428966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,2,18]]},"published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfs061","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6]]},"published":{"date-parts":[[2012,6,1]]}}}